Oral immunotherapy: The answer to peanut allergy?

Rachel M Whitsel; Jaclyn A Bjelac; Ahila Subramanian; Alice E W Hoyt; Sandra J Hong

doi:10.3949/ccjm.88a.20130

Oral immunotherapy: The answer to peanut allergy?

Cleve Clin J Med. 2021 Feb 1;88(2):104-109. doi: 10.3949/ccjm.88a.20130.

Authors

Rachel M Whitsel¹, Jaclyn A Bjelac², Ahila Subramanian³, Alice E W Hoyt⁴, Sandra J Hong⁵

Affiliations

¹ Department of Allergy and Clinical Immunology, Food Allergy Center of Excellence., Cleveland Clinic.
² Department of Pediatric Allergy and Clinical Immunology, Food Allergy Center of Excellence, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
³ Department of Allergy and Clinical Immunology, Food Allergy Center of Excellence, Cleveland Clinic.
⁴ Department of Allergy and Clinical Immunology, Food Allergy Center of Excellence, Cleveland Clinic; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
⁵ Department of Allergy and Clinical Immunology, Food Allergy Center of Excellence, Cleveland Clinic; Clinical Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH hongs3@ccf.org.

PMID: 33526464
DOI: 10.3949/ccjm.88a.20130

Abstract

Peanut and tree-nut allergies have increased dramatically in prevalence, especially in children. Historically, children with food allergies have been treated through strict avoidance of the allergen. Recently, an oral preparation of peanut allergen (Palforzia) was approved for immunotherapy (ie, desensitization) in children 4 to 17 years old. This article reviews oral immunotherapy and its role in children with peanut allergies.

Publication types

Review

MeSH terms

Adolescent
Allergens
Arachis
Child
Child, Preschool
Humans
Immunotherapy
Nut Hypersensitivity*
Peanut Hypersensitivity* / therapy

Substances

Allergens